ROYALTY PHARMA PLC — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 35 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $622M | ↑+4.8% | $214M | ↑+2.9% | 62.4% |
| 2025-09-30 | $609M | ↑+7.9% | $288M | ↓-47.0% | 70.1% |
| 2025-06-30 | $579M | ↑+7.7% | $30M | ↓-70.4% | 36.3% |
| 2025-03-31 | $568M | ↑+0.0% | $238M | ↑+4888.5% | 94.0% |
| 2024-12-31 | $594M | ↓-0.4% | $208M | ↓-57.9% | 60.9% |
| 2024-09-30 | $565M | ↑+5.3% | $544M | ↑+654.3% | 130.2% |
| 2024-06-30 | $537M | ↓-0.2% | $102M | ↓-55.2% | 50.2% |
| 2024-03-31 | $568M | ↓-17.0% | $5M | ↓-98.6% | -13.0% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$622M
↑+4.8% +$28M YoY
Net Income
$214M
↑+2.9% +$6M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
RPRX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyRPRX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics